Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that familiar routine of meetings, deadlines, and the like has returned. You knew this would happen, though, yes? After all, the world is still spinning. So what better way to cope than to hoist a few cups of stimulation? Our choice today is Southern pecan. As always, feel free to join us. Meanwhile, here are some tidbits to get you going. Hope your day is smashing and, by all means, do keep in touch …

Fresenius (FRE) walked away from a pending $4.3 billion acquisition of Akorn (AKRX), a generic drug maker, after a finding problems with product-development practices. The company found “material breaches” of Food and Drug Administration standards while reviewing Akorn operations. Fresenius offered to delay its decision until Akorn had completed its own investigation, but was turned down, setting up a potential legal battle over the aborted takeover. Akorn says it “categorically disagree[s] with [the] accusations.” Fresenius disclosed its investigation in February.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • In the matter of Pfizer’s setback, one wonders if events either in Kansas (Mc Pherson) or South Korea (Celltrion) had any impact on this – or just the general aura of anything related to the legacy Hospira?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy